First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Novo Nordisk has a strong leadership position within the growing diabetes care market Global diabetes care market by treatment class Global diabetes care value market share DKK billion 500 400 300 200 100 0 Feb 2008 OAD Slide 27 GLP-1 Insulin Novo Nordisk Sanofi - Eli Lilly J&J - Novartis AstraZeneca Merck - Takeda Boehringer Ingelheim 30% 27% Total market: CAGR¹ 15.1% Injectables: CAGR¹ 18.4% 20% 1 CAGR for 10-year period OAD: Oral Anti-diabetic Source: IQVIA MAT Feb, 2018 value figures changing diabetes® CAGR¹ 33.8% CAGR¹ 16.5% 10% CAGR¹ 11.1% 0% Feb 2018 Feb 2008 Source: IQVIA MAT Feb, 2018 value figures Feb 2018 novo nordisk

View entire presentation